You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAtazanavir
Accession NumberDB01072  (APRD00804)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAtazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. [Wikipedia]
Structure
Thumb
Synonyms
Atazanavirum
ATV
ATZ
Latazanavir
Zrivada
External Identifiers
  • BMS-232632
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Reyatazcapsule, gelatin coated150 mg/1oralPhysicians Total Care, Inc.2003-07-16Not applicableUs
Reyatazcapsule, gelatin coated300 mg/1oralE.R. Squibb & Sons, L.L.C.2003-06-24Not applicableUs
Reyatazcapsule300 mgoralBristol Myers Squibb Canada2007-05-31Not applicableCanada
Reyatazcapsule, gelatin coated150 mg/1oralREMEDYREPACK INC.2013-03-262016-03-31Us
Reyatazcapsule, gelatin coated300 mg/1oralPhysicians Total Care, Inc.2007-12-04Not applicableUs
Reyatazcapsule, gelatin coated150 mg/1oralE.R. Squibb & Sons, L.L.C.2003-06-24Not applicableUs
Reyatazcapsule100 mgoralBristol Myers Squibb CanadaNot applicableNot applicableCanada
Reyatazcapsule, gelatin coated200 mg/1oralA S Medication Solutions Llc2003-06-24Not applicableUs
Reyatazcapsule150 mgoralBristol Myers Squibb Canada2004-01-09Not applicableCanada
Reyatazcapsule, gelatin coated200 mg/1oralE.R. Squibb & Sons, L.L.C.2003-06-24Not applicableUs
Reyatazcapsule, gelatin coated300 mg/1oralA S Medication Solutions Llc2003-06-24Not applicableUs
Reyatazcapsule200 mgoralBristol Myers Squibb Canada2004-01-09Not applicableCanada
Reyatazpowder50 mg/1oralE.R. Squibb & Sons, L.L.C.2014-12-19Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LatazanavirNot Available
ZrivadaNot Available
Brand mixtures
NameLabellerIngredients
EvotazE.R. Squibb & Sons, L.L.C.
Salts
Name/CASStructureProperties
Atazanavir sulfate
229975-97-7
Thumb
  • InChI Key: DQSGVVGOPRWTKI-QVFAWCHISA-N
  • Monoisotopic Mass: 802.35712729
  • Average Mass: 802.934
DBSALT000426
Categories
UNIIQZU4H47A3S
CAS number198904-31-3
WeightAverage: 704.8555
Monoisotopic: 704.389748048
Chemical FormulaC38H52N6O7
InChI KeyInChIKey=AXRYRYVKAWYZBR-GASGPIRDSA-N
InChI
InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
IUPAC Name
methyl N-[(1S)-1-{[(2S,3S)-3-hydroxy-4-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-N'-{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate
SMILES
COC(=O)N[[email protected]](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPhenylpyridines
Direct ParentPhenylpyridines
Alternative Parents
Substituents
  • 2-phenylpyridine
  • Alpha-amino acid amide
  • Phenylbutylamine
  • Amphetamine or derivatives
  • N-substituted-alpha-amino acid
  • Phenylmethylamine
  • Benzylamine
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
PharmacodynamicsAtazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Atazanivir is pharmacologically related but structurally different from other protease inhibitors and other currently available antiretrovirals.
Mechanism of actionAtazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2.
Related Articles
AbsorptionAtazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Oral bioavailability is 60-68%.
Volume of distributionNot Available
Protein binding86% bound to human serum proteins (alpha-1-acid glycoprotein and albumin). Protein binding is independent of concentration.
Metabolism

Atazanavir is extensively metabolized in humans, primarily by the liver. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.

Route of eliminationNot Available
Half lifeElimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7997
Blood Brain Barrier-0.9409
Caco-2 permeable-0.7017
P-glycoprotein substrateSubstrate0.832
P-glycoprotein inhibitor IInhibitor0.81
P-glycoprotein inhibitor IINon-inhibitor0.844
Renal organic cation transporterNon-inhibitor0.924
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6463
CYP450 1A2 substrateNon-inhibitor0.7553
CYP450 2C9 inhibitorNon-inhibitor0.7041
CYP450 2D6 inhibitorNon-inhibitor0.848
CYP450 2C19 inhibitorNon-inhibitor0.5948
CYP450 3A4 inhibitorNon-inhibitor0.8425
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7718
Ames testNon AMES toxic0.6714
CarcinogenicityNon-carcinogens0.7261
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7082 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9766
hERG inhibition (predictor II)Inhibitor0.6538
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Capsuleoral100 mg
Capsuleoral150 mg
Capsuleoral200 mg
Capsuleoral300 mg
Capsule, gelatin coatedoral150 mg/1
Capsule, gelatin coatedoral200 mg/1
Capsule, gelatin coatedoral300 mg/1
Powderoral50 mg/1
Prices
Unit descriptionCostUnit
Reyataz 300 mg capsule36.63USD capsule
Reyataz 150 mg capsule18.49USD capsule
Reyataz 200 mg capsule18.49USD capsule
Reyataz 100 mg capsule18.12USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2250840 No2006-07-042017-04-14Canada
CA2317736 No2004-11-022018-12-22Canada
US5849911 Yes1997-12-202017-12-20Us
US6087383 Yes1999-06-212019-06-21Us
US8148374 No2009-09-032029-09-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFree base slightly soluble (4-5 mg/mL)Not Available
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP4.08ALOGPS
logP4.54ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.92ChemAxon
pKa (Strongest Basic)4.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area171.22 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity191.8 m3·mol-1ChemAxon
Polarizability76.83 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US5849911
General References
  1. Croom KF, Dhillon S, Keam SJ: Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009 May 29;69(8):1107-40. doi: 10.2165/00003495-200969080-00009. [PubMed:19496633 ]
  2. von Hentig N: Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. [PubMed:18389089 ]
  3. Swainston Harrison T, Scott LJ: Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005;65(16):2309-36. [PubMed:16266202 ]
  4. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. [PubMed:16176117 ]
  5. Lopez-Cortes LF: [Pharmacology, pharmacokinetic features and interactions of atazanavir]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8. [PubMed:20116610 ]
  6. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441 ]
External Links
ATC CodesJ05AE08J05AR15
AHFS Codes
  • 08:18.08.08
PDB EntriesNot Available
FDA labelDownload (412 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Atazanavir.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Atazanavir.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Atazanavir.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Atazanavir.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Atazanavir.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Atazanavir.
AcetaminophenThe serum concentration of Atazanavir can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Atazanavir.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Atazanavir.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Atazanavir.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atazanavir.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Atazanavir.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Atazanavir.
AlbendazoleThe serum concentration of Atazanavir can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Atazanavir.
AldosteroneThe serum concentration of Atazanavir can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Atazanavir.
AlectinibThe serum concentration of Atazanavir can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Atazanavir.
AlfentanilThe serum concentration of Atazanavir can be increased when it is combined with Alfentanil.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Atazanavir.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Atazanavir.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Atazanavir.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Atazanavir.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Atazanavir.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Atazanavir.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Atazanavir.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Atazanavir.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmantadineThe serum concentration of Atazanavir can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Atazanavir.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Atazanavir.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Atazanavir.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Atazanavir.
Aminohippuric acidThe serum concentration of Atazanavir can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Atazanavir.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Atazanavir.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Atazanavir.
AmiodaroneThe serum concentration of Atazanavir can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Atazanavir.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Atazanavir.
AmlodipineThe serum concentration of Atazanavir can be increased when it is combined with Amlodipine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Atazanavir.
AmprenavirThe serum concentration of Atazanavir can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Atazanavir can be increased when it is combined with Amsacrine.
AnagrelideAtazanavir may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Atazanavir.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Atazanavir.
ApremilastThe metabolism of Apremilast can be decreased when combined with Atazanavir.
AprepitantThe serum concentration of Atazanavir can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Atazanavir.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Atazanavir.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Atazanavir.
ArtemetherThe metabolism of Artemether can be decreased when combined with Atazanavir.
AsenapineThe serum concentration of Atazanavir can be decreased when it is combined with Asenapine.
AsenapineThe metabolism of Asenapine can be decreased when combined with Atazanavir.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atazanavir can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Atazanavir can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Atazanavir.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Atazanavir.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Atazanavir.
AzelastineThe metabolism of Azelastine can be decreased when combined with Atazanavir.
AzelastineThe serum concentration of Atazanavir can be increased when it is combined with Azelastine.
AzithromycinAtazanavir may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Atazanavir can be increased when it is combined with Azithromycin.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Atazanavir.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Atazanavir.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Atazanavir.
BedaquilineAtazanavir may increase the QTc-prolonging activities of Bedaquiline.
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Atazanavir.
BenzocaineThe serum concentration of Atazanavir can be increased when it is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Atazanavir.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Atazanavir.
BepridilThe serum concentration of Atazanavir can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Atazanavir.
BexaroteneThe serum concentration of Atazanavir can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Atazanavir.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Atazanavir.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Atazanavir.
BiperidenThe serum concentration of Atazanavir can be increased when it is combined with Biperiden.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Atazanavir.
BoceprevirThe serum concentration of Atazanavir can be decreased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Atazanavir.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Atazanavir.
BortezomibThe metabolism of Atazanavir can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Atazanavir can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Atazanavir.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atazanavir.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atazanavir.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Atazanavir.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Atazanavir.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Atazanavir.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Atazanavir.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Atazanavir.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Atazanavir.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Atazanavir.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Atazanavir.
BuprenorphineThe serum concentration of Atazanavir can be decreased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Atazanavir.
BupropionThe metabolism of Bupropion can be decreased when combined with Atazanavir.
BuspironeThe metabolism of Buspirone can be decreased when combined with Atazanavir.
BuspironeThe serum concentration of Atazanavir can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Atazanavir.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Atazanavir.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Atazanavir.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Atazanavir.
CaffeineThe serum concentration of Atazanavir can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Atazanavir.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Atazanavir.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Atazanavir.
CanagliflozinThe serum concentration of Atazanavir can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Atazanavir can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Atazanavir can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Atazanavir can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Atazanavir can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Atazanavir.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Atazanavir.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Atazanavir.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Atazanavir.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Atazanavir.
CarvedilolThe serum concentration of Atazanavir can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Atazanavir can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Atazanavir.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Atazanavir.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Atazanavir.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Atazanavir.
CeritinibThe serum concentration of Atazanavir can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Atazanavir.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Atazanavir.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Atazanavir.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Atazanavir.
ChloroquineAtazanavir may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Atazanavir can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Atazanavir.
ChlorpromazineAtazanavir may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Atazanavir can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Atazanavir.
ChlorpropamideThe serum concentration of Atazanavir can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Atazanavir can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Atazanavir.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Atazanavir.
CholesterolThe serum concentration of Atazanavir can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Atazanavir can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Atazanavir.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Atazanavir.
CilazaprilThe serum concentration of Atazanavir can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Atazanavir.
CimetidineThe serum concentration of Atazanavir can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Atazanavir.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Atazanavir.
CiprofloxacinAtazanavir may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Atazanavir can be increased when it is combined with Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Atazanavir.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Atazanavir.
CitalopramThe serum concentration of Atazanavir can be increased when it is combined with Citalopram.
ClarithromycinAtazanavir may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Atazanavir can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Atazanavir can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Atazanavir.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Atazanavir.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Atazanavir.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Atazanavir.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Atazanavir.
ClofazimineThe serum concentration of Atazanavir can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Atazanavir.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Atazanavir.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Atazanavir.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Atazanavir.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Atazanavir.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Atazanavir.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Atazanavir.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Atazanavir.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Atazanavir.
ClotrimazoleThe metabolism of Atazanavir can be decreased when combined with Clotrimazole.
ClozapineAtazanavir may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Atazanavir can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atazanavir.
CocaineThe metabolism of Cocaine can be decreased when combined with Atazanavir.
CodeineThe metabolism of Codeine can be decreased when combined with Atazanavir.
ColchicineThe serum concentration of Atazanavir can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Atazanavir can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Atazanavir can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Atazanavir.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Atazanavir.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Atazanavir.
CrizotinibThe metabolism of Atazanavir can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Atazanavir.
CyclophosphamideThe risk or severity of adverse effects can be increased when Atazanavir is combined with Cyclophosphamide.
CyclophosphamideThe serum concentration of Atazanavir can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Atazanavir can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Atazanavir.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Atazanavir.
DabrafenibThe serum concentration of Atazanavir can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Atazanavir.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Atazanavir.
DactinomycinThe serum concentration of Atazanavir can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Atazanavir.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Atazanavir.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Atazanavir.
DapsoneThe metabolism of Dapsone can be decreased when combined with Atazanavir.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Atazanavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Atazanavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Atazanavir.
DasatinibThe serum concentration of Atazanavir can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Atazanavir can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Atazanavir.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Atazanavir.
DeferasiroxThe serum concentration of Atazanavir can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Atazanavir.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Atazanavir.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Atazanavir.
DelavirdineThe metabolism of Atazanavir can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Atazanavir.
DesloratadineThe serum concentration of Atazanavir can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Atazanavir.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Atazanavir.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Atazanavir.
DexamethasoneThe serum concentration of Atazanavir can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Atazanavir.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Atazanavir.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Atazanavir.
DextromethorphanThe serum concentration of Atazanavir can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Atazanavir.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Atazanavir.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Atazanavir.
DiclofenacThe serum concentration of Atazanavir can be increased when it is combined with Diclofenac.
DidanosineThe serum concentration of Atazanavir can be decreased when it is combined with Didanosine.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Atazanavir.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atazanavir.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Atazanavir.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Atazanavir.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Atazanavir.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Atazanavir.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Atazanavir.
DigoxinThe serum concentration of Atazanavir can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Atazanavir.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Atazanavir.
DihydroergotamineThe metabolism of Atazanavir can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Atazanavir.
DiltiazemThe metabolism of Atazanavir can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Atazanavir.
DipyridamoleThe serum concentration of Atazanavir can be increased when it is combined with Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Atazanavir.
DisulfiramThe therapeutic efficacy of Disulfiram can be decreased when used in combination with Atazanavir.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Atazanavir.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Atazanavir.
DolasetronAtazanavir may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atazanavir.
DonepezilThe metabolism of Donepezil can be decreased when combined with Atazanavir.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Atazanavir.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Atazanavir.
DoxazosinThe serum concentration of Atazanavir can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Atazanavir.
DoxorubicinThe serum concentration of Atazanavir can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atazanavir.
DoxycyclineThe metabolism of Atazanavir can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Atazanavir.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Atazanavir.
DronedaroneThe metabolism of Atazanavir can be decreased when combined with Dronedarone.
DroperidolAtazanavir may increase the QTc-prolonging activities of Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Atazanavir.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Atazanavir.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Atazanavir.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Atazanavir.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atazanavir.
EfavirenzThe serum concentration of Atazanavir can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Atazanavir.
ElbasvirThe serum concentration of Atazanavir can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Atazanavir.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Atazanavir.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Atazanavir.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Atazanavir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Atazanavir.
EnalaprilThe serum concentration of Atazanavir can be increased when it is combined with Enalapril.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Atazanavir.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Atazanavir.
EpinastineThe serum concentration of Atazanavir can be decreased when it is combined with Epinastine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Atazanavir.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Atazanavir.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Atazanavir.
EquilinThe serum concentration of Equilin can be increased when it is combined with Atazanavir.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Atazanavir.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Atazanavir.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Atazanavir.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Atazanavir.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Atazanavir.
ErythromycinAtazanavir may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Atazanavir can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Atazanavir.
Eslicarbazepine acetateThe serum concentration of Atazanavir can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Atazanavir.
EsomeprazoleThe serum concentration of Atazanavir can be decreased when it is combined with Esomeprazole.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Atazanavir.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Atazanavir.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Atazanavir.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Atazanavir.
EstramustineThe metabolism of Estramustine can be decreased when combined with Atazanavir.
EstramustineThe serum concentration of Atazanavir can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Atazanavir can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Atazanavir.
EstroneThe serum concentration of Atazanavir can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Atazanavir.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Atazanavir.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Atazanavir.
EthanolThe metabolism of Ethanol can be decreased when combined with Atazanavir.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Atazanavir.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Atazanavir.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Atazanavir.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Atazanavir.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Atazanavir.
EtoposideThe serum concentration of Atazanavir can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Atazanavir.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Atazanavir.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atazanavir.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Atazanavir.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Atazanavir.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Atazanavir.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Atazanavir.
FamotidineThe serum concentration of Atazanavir can be decreased when it is combined with Famotidine.
FelbamateThe metabolism of Felbamate can be decreased when combined with Atazanavir.
FelodipineThe metabolism of Felodipine can be decreased when combined with Atazanavir.
FelodipineThe serum concentration of Atazanavir can be increased when it is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Atazanavir.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Atazanavir.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Atazanavir.
FexofenadineThe serum concentration of Atazanavir can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Atazanavir.
FinasterideThe metabolism of Finasteride can be decreased when combined with Atazanavir.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Atazanavir.
FlecainideAtazanavir may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Atazanavir.
FloxuridineThe metabolism of Atazanavir can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Atazanavir can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Atazanavir.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Atazanavir.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Atazanavir.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Atazanavir.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Atazanavir.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Atazanavir.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Atazanavir.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Atazanavir.
FluorouracilThe metabolism of Atazanavir can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Atazanavir.
FluoxetineThe serum concentration of Atazanavir can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Atazanavir can be increased when it is combined with Flupentixol.
FlupentixolAtazanavir may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Atazanavir can be increased when it is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Atazanavir.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Atazanavir.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Atazanavir.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Atazanavir.
FlurazepamThe serum concentration of Atazanavir can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Atazanavir.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Atazanavir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Atazanavir.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Atazanavir.
FluvastatinThe metabolism of Atazanavir can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Atazanavir can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Atazanavir can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Atazanavir can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Atazanavir can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Atazanavir.
Fusidic AcidThe serum concentration of Atazanavir can be increased when it is combined with Fusidic Acid.
Gadobenic acidAtazanavir may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Atazanavir.
GarlicThe serum concentration of Atazanavir can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Atazanavir can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Atazanavir.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Atazanavir.
GemifloxacinAtazanavir may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Atazanavir can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Atazanavir.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Atazanavir.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Atazanavir.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Atazanavir.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Atazanavir.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Atazanavir.
GlyburideThe serum concentration of Atazanavir can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Atazanavir can be increased when it is combined with Glycerol.
GoserelinAtazanavir may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Atazanavir can be increased when it is combined with Gramicidin D.
GranisetronAtazanavir may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Atazanavir.
GrepafloxacinThe serum concentration of Atazanavir can be increased when it is combined with Grepafloxacin.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Atazanavir.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Atazanavir.
HaloperidolAtazanavir may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Atazanavir can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Atazanavir.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Atazanavir.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Atazanavir.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Atazanavir.
HydrocortisoneThe serum concentration of Atazanavir can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Atazanavir.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Atazanavir.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Atazanavir.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Atazanavir.
IbutilideAtazanavir may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Atazanavir can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Atazanavir resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Atazanavir.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Atazanavir.
ImatinibThe metabolism of Atazanavir can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Atazanavir.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Atazanavir.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Atazanavir.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Atazanavir.
IndapamideThe metabolism of Indapamide can be decreased when combined with Atazanavir.
IndinavirThe risk or severity of adverse effects can be increased when Atazanavir is combined with Indinavir.
IndinavirThe serum concentration of Atazanavir can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Atazanavir can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Atazanavir.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Atazanavir.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Atazanavir.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Atazanavir.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Atazanavir.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Atazanavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Atazanavir.
IrbesartanThe metabolism of Atazanavir can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Atazanavir.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Atazanavir.
IsavuconazoniumThe metabolism of Atazanavir can be decreased when combined with Isavuconazonium.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Atazanavir.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atazanavir.
IsradipineThe metabolism of Atazanavir can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Atazanavir.
ItraconazoleThe serum concentration of Atazanavir can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Atazanavir.
IvacaftorThe serum concentration of Atazanavir can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Atazanavir can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Atazanavir.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Atazanavir.
KetamineThe metabolism of Ketamine can be decreased when combined with Atazanavir.
KetamineThe serum concentration of Atazanavir can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Atazanavir.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Atazanavir.
KetoconazoleThe serum concentration of Atazanavir can be increased when it is combined with Ketoconazole.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Atazanavir.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Atazanavir.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Atazanavir.
LansoprazoleThe serum concentration of Atazanavir can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Atazanavir.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Atazanavir.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atazanavir.
LeflunomideThe metabolism of Atazanavir can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Atazanavir.
LenvatinibAtazanavir may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Atazanavir.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Atazanavir.
LeuprolideAtazanavir may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Atazanavir.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Atazanavir.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Atazanavir.
LevofloxacinAtazanavir may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Atazanavir can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Atazanavir.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Atazanavir.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Atazanavir.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Atazanavir.
LevothyroxineThe serum concentration of Atazanavir can be decreased when it is combined with Levothyroxine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Atazanavir.
LidocaineThe serum concentration of Atazanavir can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Atazanavir.
LiothyronineThe serum concentration of Atazanavir can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Atazanavir can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Atazanavir.
LisinoprilThe serum concentration of Atazanavir can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Atazanavir.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Atazanavir.
LoperamideThe serum concentration of Atazanavir can be increased when it is combined with Loperamide.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Atazanavir.
LopinavirThe serum concentration of Atazanavir can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Atazanavir.
LoratadineThe serum concentration of Atazanavir can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Atazanavir.
LosartanThe serum concentration of Atazanavir can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Atazanavir.
LovastatinThe metabolism of Atazanavir can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Atazanavir can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Atazanavir can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Atazanavir.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Atazanavir.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Atazanavir.
MagaldrateMagaldrate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Atazanavir.
MaprotilineThe serum concentration of Atazanavir can be increased when it is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Atazanavir.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Atazanavir.
MebendazoleThe serum concentration of Atazanavir can be increased when it is combined with Mebendazole.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Atazanavir.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Atazanavir.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Atazanavir.
MefloquineThe serum concentration of Atazanavir can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Atazanavir can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Atazanavir.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Atazanavir.
MeprobamateThe serum concentration of Atazanavir can be increased when it is combined with Meprobamate.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.
MethadoneAtazanavir may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Atazanavir can be increased when it is combined with Methadone.
MethanthelineThe serum concentration of Atazanavir can be decreased when it is combined with Methantheline.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Atazanavir.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Atazanavir.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Atazanavir.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Atazanavir.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Atazanavir.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Atazanavir.
MetiamideThe serum concentration of Atazanavir can be decreased when it is combined with Metiamide.
MetoprololThe serum concentration of Atazanavir can be increased when it is combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Atazanavir.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Atazanavir.
MianserinThe metabolism of Mianserin can be decreased when combined with Atazanavir.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Atazanavir.
MibefradilThe serum concentration of Atazanavir can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Atazanavir.
MiconazoleThe serum concentration of Atazanavir can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Atazanavir.
MidazolamThe serum concentration of Atazanavir can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Atazanavir.
MifepristoneThe metabolism of Atazanavir can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Atazanavir.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Atazanavir.
MinocyclineThe serum concentration of Atazanavir can be decreased when it is combined with Minocycline.
MinoxidilThe serum concentration of Minoxidil can be increased when it is combined with Atazanavir.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Atazanavir.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Atazanavir.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Atazanavir.
MitomycinThe serum concentration of Atazanavir can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Atazanavir can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Atazanavir can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Atazanavir.
ModafinilThe serum concentration of Atazanavir can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Atazanavir.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Atazanavir.
MontelukastThe metabolism of Montelukast can be decreased when combined with Atazanavir.
MorphineThe serum concentration of Atazanavir can be increased when it is combined with Morphine.
MoxifloxacinAtazanavir may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atazanavir.
NadololThe serum concentration of Nadolol can be increased when it is combined with Atazanavir.
NafcillinThe serum concentration of Atazanavir can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atazanavir.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Atazanavir.
NaltrexoneThe serum concentration of Atazanavir can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Atazanavir can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Atazanavir.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Atazanavir.
NefazodoneThe serum concentration of Atazanavir can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Atazanavir can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Atazanavir.
NeostigmineThe serum concentration of Atazanavir can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Atazanavir can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Atazanavir.
NevirapineThe metabolism of Atazanavir can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Atazanavir can be increased when it is combined with Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Atazanavir.
NifedipineThe serum concentration of Atazanavir can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Atazanavir.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Atazanavir.
NilotinibThe metabolism of Atazanavir can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Atazanavir.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Atazanavir.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atazanavir.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Atazanavir.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Atazanavir.
NitrazepamThe serum concentration of Atazanavir can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Atazanavir.
NitrendipineThe serum concentration of Atazanavir can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Atazanavir can be decreased when it is combined with Nizatidine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Atazanavir.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Atazanavir.
NorethisteroneThe serum concentration of Atazanavir can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Atazanavir.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Atazanavir.
OfloxacinAtazanavir may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Atazanavir can be decreased when it is combined with Olanzapine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Atazanavir.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Atazanavir.
OlaparibThe metabolism of Atazanavir can be decreased when combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Atazanavir.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Atazanavir.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Atazanavir.
OmeprazoleThe serum concentration of Atazanavir can be increased when it is combined with Omeprazole.
OndansetronAtazanavir may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Atazanavir.
OsimertinibThe serum concentration of Atazanavir can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Atazanavir.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Atazanavir.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Atazanavir.
OxycodoneThe risk or severity of adverse effects can be increased when Atazanavir is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Atazanavir.
P-NitrophenolThe serum concentration of Atazanavir can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.
PalbociclibThe serum concentration of Atazanavir can be increased when it is combined with Palbociclib.
PaliperidoneAtazanavir may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Atazanavir can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Atazanavir.
PanobinostatAtazanavir may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Atazanavir.
PantoprazoleThe serum concentration of Atazanavir can be increased when it is combined with Pantoprazole.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Atazanavir.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Atazanavir.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Atazanavir.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Atazanavir.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Atazanavir.
ParoxetineThe serum concentration of Atazanavir can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Atazanavir.
PentamidineAtazanavir may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Atazanavir can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Atazanavir.
PerflutrenAtazanavir may increase the QTc-prolonging activities of Perflutren.
PergolideThe metabolism of Pergolide can be decreased when combined with Atazanavir.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Atazanavir.
PerindoprilThe serum concentration of Atazanavir can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Atazanavir.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Atazanavir.
PethidineThe risk or severity of adverse effects can be increased when Atazanavir is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Atazanavir.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Atazanavir.
PhenobarbitalThe serum concentration of Atazanavir can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Atazanavir.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Atazanavir.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Atazanavir.
PhenytoinThe metabolism of Atazanavir can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Atazanavir.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Atazanavir.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Atazanavir.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Atazanavir.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Atazanavir.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Atazanavir.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Atazanavir.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atazanavir.
Platelet Activating FactorThe serum concentration of Atazanavir can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Atazanavir.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Atazanavir.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Atazanavir.
PosaconazoleThe serum concentration of Atazanavir can be increased when it is combined with Posaconazole.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Atazanavir.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Atazanavir.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Atazanavir.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Atazanavir resulting in a loss in efficacy.
PravastatinThe serum concentration of Atazanavir can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Atazanavir.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Atazanavir.
PrazosinThe serum concentration of Atazanavir can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Atazanavir.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Atazanavir.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Atazanavir.
PrimaquineAtazanavir may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Atazanavir can be increased when combined with Primidone.
ProbenecidThe serum concentration of Atazanavir can be increased when it is combined with Probenecid.
ProcainamideAtazanavir may increase the QTc-prolonging activities of Procainamide.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Atazanavir.
ProgesteroneThe serum concentration of Atazanavir can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Atazanavir.
ProguanilThe metabolism of Proguanil can be decreased when combined with Atazanavir.
PromazineAtazanavir may increase the QTc-prolonging activities of Promazine.
PromethazineThe serum concentration of Atazanavir can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Atazanavir.
PropofolThe metabolism of Propofol can be decreased when combined with Atazanavir.
PropranololThe serum concentration of Atazanavir can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Atazanavir.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atazanavir.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Atazanavir.
PyrimethamineThe metabolism of Atazanavir can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Atazanavir.
QuercetinThe serum concentration of Atazanavir can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Atazanavir.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Atazanavir.
QuinacrineThe serum concentration of Atazanavir can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Atazanavir.
QuinineThe serum concentration of Atazanavir can be increased when it is combined with Quinine.
RabeprazoleThe serum concentration of Atazanavir can be decreased when it is combined with Rabeprazole.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Atazanavir.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Atazanavir.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Atazanavir.
RanitidineThe serum concentration of Atazanavir can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Atazanavir can be increased when it is combined with Ranolazine.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Atazanavir.
ReboxetineThe serum concentration of Atazanavir can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Atazanavir.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Atazanavir.
ReserpineThe serum concentration of Atazanavir can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Atazanavir.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Atazanavir.
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Atazanavir.
RifabutinThe metabolism of Atazanavir can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Atazanavir can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Atazanavir.
RifapentineThe metabolism of Atazanavir can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atazanavir.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Atazanavir.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Atazanavir.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Atazanavir.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Atazanavir.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Atazanavir.
RitonavirThe serum concentration of Atazanavir can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Atazanavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Atazanavir.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Atazanavir.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Atazanavir.
RolapitantThe serum concentration of Atazanavir can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Atazanavir.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Atazanavir.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Atazanavir.
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Atazanavir.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Atazanavir.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Atazanavir.
Roxatidine acetateThe serum concentration of Atazanavir can be decreased when it is combined with Roxatidine acetate.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Atazanavir.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Atazanavir.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Atazanavir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Atazanavir.
SaquinavirAtazanavir may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Atazanavir can be decreased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Atazanavir.
ScopolamineThe serum concentration of Atazanavir can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Atazanavir can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Atazanavir.
SelegilineThe serum concentration of Atazanavir can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Atazanavir.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Atazanavir.
SertindoleThe metabolism of Sertindole can be decreased when combined with Atazanavir.
SertralineThe metabolism of Sertraline can be decreased when combined with Atazanavir.
SertralineThe serum concentration of Atazanavir can be increased when it is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Atazanavir.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Atazanavir.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Atazanavir.
SildenafilThe metabolism of Atazanavir can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atazanavir.
SiltuximabThe serum concentration of Atazanavir can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Atazanavir can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Atazanavir.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Atazanavir.
SirolimusThe serum concentration of Atazanavir can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Atazanavir.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Atazanavir.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Atazanavir.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Atazanavir.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Atazanavir.
SotalolAtazanavir may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Atazanavir.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Atazanavir.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Atazanavir.
SpironolactoneThe serum concentration of Atazanavir can be increased when it is combined with Spironolactone.
St. John's WortThe metabolism of Atazanavir can be increased when combined with St. John's Wort.
StaurosporineThe serum concentration of Atazanavir can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Atazanavir can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Atazanavir can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Atazanavir.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Atazanavir.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Atazanavir.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Atazanavir.
SulfinpyrazoneThe serum concentration of Atazanavir can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleAtazanavir may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Atazanavir can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Atazanavir.
SumatriptanThe serum concentration of Atazanavir can be increased when it is combined with Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Atazanavir.
SunitinibThe serum concentration of Atazanavir can be increased when it is combined with Sunitinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Atazanavir.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Atazanavir.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Atazanavir.
TacrineThe serum concentration of Atazanavir can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Atazanavir.
TacrolimusThe serum concentration of Atazanavir can be decreased when it is combined with Tacrolimus.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Atazanavir.
TAK-390MRThe serum concentration of Atazanavir can be decreased when it is combined with TAK-390MR.
TamoxifenThe serum concentration of Atazanavir can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Atazanavir.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Atazanavir.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Atazanavir.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Atazanavir.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Atazanavir.
Taurocholic AcidThe serum concentration of Atazanavir can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Atazanavir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Atazanavir.
TelaprevirThe metabolism of Atazanavir can be decreased when combined with Telaprevir.
TelavancinAtazanavir may increase the QTc-prolonging activities of Telavancin.
TelithromycinAtazanavir may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Atazanavir can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Atazanavir can be increased when it is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Atazanavir.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Atazanavir.
TeniposideThe metabolism of Teniposide can be decreased when combined with Atazanavir.
TenofovirThe serum concentration of Atazanavir can be decreased when it is combined with Tenofovir.
TerazosinThe serum concentration of Atazanavir can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Atazanavir.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Atazanavir.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Atazanavir.
TesmilifeneThe serum concentration of Atazanavir can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Atazanavir.
TestosteroneThe serum concentration of Atazanavir can be increased when it is combined with Testosterone.
TetrabenazineAtazanavir may increase the QTc-prolonging activities of Tetrabenazine.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Atazanavir.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Atazanavir.
ThioridazineAtazanavir may increase the QTc-prolonging activities of Thioridazine.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Atazanavir.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Atazanavir.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Atazanavir.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Atazanavir resulting in a loss in efficacy.
TicagrelorThe serum concentration of Atazanavir can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Atazanavir can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Atazanavir.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Atazanavir.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Atazanavir.
TipranavirThe serum concentration of Atazanavir can be decreased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Atazanavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Atazanavir.
TocilizumabThe serum concentration of Atazanavir can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Atazanavir.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Atazanavir.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Atazanavir.
TolbutamideThe metabolism of Atazanavir can be decreased when combined with Tolbutamide.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Atazanavir.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atazanavir.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Atazanavir.
ToremifeneThe risk or severity of adverse effects can be increased when Atazanavir is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Atazanavir.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Atazanavir.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Atazanavir.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Atazanavir.
TrazodoneThe serum concentration of Atazanavir can be decreased when it is combined with Trazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Atazanavir.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Atazanavir.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Atazanavir.
TrifluoperazineThe serum concentration of Atazanavir can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Atazanavir can be increased when it is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Atazanavir.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Atazanavir.
TrimethoprimThe serum concentration of Atazanavir can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Atazanavir.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Atazanavir.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Atazanavir.
TroleandomycinThe serum concentration of Atazanavir can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Atazanavir.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atazanavir.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Atazanavir.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Atazanavir.
Valproic AcidThe metabolism of Atazanavir can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Atazanavir can be decreased when combined with Valsartan.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Atazanavir.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Atazanavir.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Atazanavir.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Atazanavir.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Atazanavir.
VenlafaxineThe metabolism of Atazanavir can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Atazanavir.
VerapamilThe metabolism of Atazanavir can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Atazanavir.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Atazanavir.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Atazanavir.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Atazanavir.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Atazanavir.
VinblastineThe serum concentration of Atazanavir can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Atazanavir.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Atazanavir.
VincristineThe serum concentration of Atazanavir can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Atazanavir.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Atazanavir.
VinorelbineThe serum concentration of Atazanavir can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Atazanavir.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Atazanavir.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Atazanavir.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Atazanavir.
VoriconazoleThe metabolism of Atazanavir can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Atazanavir.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Atazanavir.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Atazanavir.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Atazanavir.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Atazanavir.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Atazanavir.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Atazanavir.
ZileutonThe metabolism of Zileuton can be decreased when combined with Atazanavir.
ZimelidineThe serum concentration of Atazanavir can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Atazanavir can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Atazanavir.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Atazanavir.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Atazanavir.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Atazanavir.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Atazanavir.
Food Interactions
  • Administration with food reduces pharmacokinetic variability.
  • Food increases product absorption.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K: Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007 Dec;81(24):13845-51. Epub 2007 Oct 10. [PubMed:17928344 ]
  2. Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694 ]
  3. Wood R: Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785. [PubMed:19053892 ]
  4. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. [PubMed:16176117 ]
  5. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC: HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67(22):10920-8. [PubMed:18006837 ]
  6. Menendez-Arias L, Tozser J: HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci. 2008 Jan;29(1):42-9. Epub 2007 Dec 4. [PubMed:18054799 ]
  7. Lopez-Cortes LF: [Pharmacology, pharmacokinetic features and interactions of atazanavir]. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. doi: 10.1016/S0213-005X(08)76613-8. [PubMed:20116610 ]
  8. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. [PubMed:16176117 ]
  2. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. [PubMed:15585441 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL: Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70. Epub 2005 Mar 11. [PubMed:15764714 ]
  2. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):635-7. [PubMed:16044020 ]
  3. Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz DL: Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother. 2007 Jul;60(1):61-7. Epub 2007 May 17. [PubMed:17510066 ]
  4. Wood R: Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785. [PubMed:19053892 ]
  5. Janneh O, Anwar T, Jungbauer C, Kopp S, Khoo SH, Back DJ, Chiba P: P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther. 2009;14(7):965-74. doi: 10.3851/IMP1399. [PubMed:19918100 ]
  6. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J: Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007 May 15;73(10):1573-81. Epub 2007 Jan 24. [PubMed:17328866 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Janneh O, Anwar T, Jungbauer C, Kopp S, Khoo SH, Back DJ, Chiba P: P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther. 2009;14(7):965-74. doi: 10.3851/IMP1399. [PubMed:19918100 ]
  2. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):635-7. [PubMed:16044020 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40